The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about the use of denosumab (Xgeva) for the prevention of skeletal-related events due to bone metastases from solid tumours.
The information gathered from this survey will be used in order to prepare a patient evidence submission to the CADTH Common Drug Review. Please note that your personal information is never shared or disclosed, but is used only by CCSN for input for statistical purposes.
This survey will be open until noon on June 11, 2015 to enable us to prepare our patient evidence submission on June 16, 2015.
Access the survey at https://www.surveymonkey.com/s/2CK7HD9